Comment
doi: 10.1016/j.ccr.2011.03.020.
Resisting targeted therapy: fifty ways to leave your EGFR
Affiliations
- PMID: 21481786
- DOI: 10.1016/j.ccr.2011.03.020
Item in Clipboard
Comment
Resisting targeted therapy: fifty ways to leave your EGFR
Cancer Cell.
.
Free article
Abstract
Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.
Copyright © 2011 Elsevier Inc. All rights reserved.
Comment on
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003. Sci Transl Med. 2011. PMID: 21430269 Free PMC article.
-
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.Nature. 2011 Mar 24;471(7339):523-6. doi: 10.1038/nature09870. Nature. 2011. PMID: 21430781 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
